DeepMed Research

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00002135

Locations: 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States

Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections

Not Applicable

Completed

Conditions: Cytomegalovirus Infections
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00002024

Locations: 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States

A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT00002367

Locations: 🇺🇸
AIDS Healthcare Foundation Labs, Los Angeles, California, United States
🇺🇸
Urgent Care Ctr / North Broward Hosp District, Fort Lauderdale, Florida, United States

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00002299

Locations: 🇺🇸
UCI Med Ctr, Orange, California, United States
🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
USC, Los Angeles, California, United States

and more 3 locations

Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00002081

Locations: 🇺🇸
ddC Coordinating Ctr, Wellesley Hills, Massachusetts, United States

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

Not Applicable

Completed

Conditions: Cytomegalovirus Infections
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 700

Registration Number: NCT00002095

Locations: 🇺🇸
Kraus - Beer Med Group, Los Angeles, California, United States
🇺🇸
Beth Israel Hosp, Boston, Massachusetts, United States
🇺🇸
UCSD, San Diego, California, United States

and more 16 locations

Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

Phase 3

Completed

Conditions: HIV Infections
Psoriasis

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT00002143

Locations: 🇺🇸
Beth Israel Med Ctr, New York, New York, United States

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 375

Registration Number: NCT00002178

Locations: 🇺🇸
Dr Charles Farthing, Los Angeles, California, United States
🇺🇸
Community Research Initiative, Brookline, Massachusetts, United States

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease

Phase 3

Completed

Conditions: HIV Infections
AIDS-Associated Nephropathy

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT00002397

Locations: 🇺🇸
Mount Sinai Med Ctr, New York, New York, United States

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT00002383

Locations: 🇺🇸
Harkness Pavilion, New York, New York, United States
🇺🇸
Mt Zion Hosp of UCSF / HIV Research Ctr, San Francisco, California, United States
🇺🇸
Davis Med Ctr, San Francisco, California, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy